Omar Eton

3.8k total citations
69 papers, 2.6k citations indexed

About

Omar Eton is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Omar Eton has authored 69 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 27 papers in Molecular Biology and 21 papers in Immunology. Recurrent topics in Omar Eton's work include Immunotherapy and Immune Responses (20 papers), Melanoma and MAPK Pathways (17 papers) and CAR-T cell therapy research (15 papers). Omar Eton is often cited by papers focused on Immunotherapy and Immune Responses (20 papers), Melanoma and MAPK Pathways (17 papers) and CAR-T cell therapy research (15 papers). Omar Eton collaborates with scholars based in United States, Australia and Brazil. Omar Eton's co-authors include Carl Plager, Agop Y. Bedikian, Antônio C. Buzaid, Sigrid Ring, Sewa S. Legha, S S Legha, Robert S. Benjamin, Nikolaos G. Papadopoulos, Nicholas E. Papadopoulos and Nickolas Papadopoulos and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Omar Eton

68 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Omar Eton United States 26 1.9k 1.3k 885 288 201 69 2.6k
Daniel O. Persky United States 30 1.2k 0.6× 732 0.6× 586 0.7× 161 0.6× 215 1.1× 110 2.6k
Jeff Sosman United States 20 1.2k 0.6× 1.2k 0.9× 498 0.6× 301 1.0× 101 0.5× 38 2.2k
Chuanliang Cui China 28 2.0k 1.1× 1.4k 1.1× 667 0.8× 385 1.3× 96 0.5× 151 2.9k
Thinle Chodon United States 22 3.2k 1.6× 3.3k 2.6× 1.4k 1.6× 422 1.5× 297 1.5× 33 5.2k
Stan Lipkowitz United States 23 1.2k 0.6× 1.9k 1.5× 978 1.1× 218 0.8× 172 0.9× 29 3.0k
Kimberly B. Dahlman United States 21 1.7k 0.9× 2.3k 1.8× 451 0.5× 460 1.6× 225 1.1× 38 3.2k
Nicholas W. Choong United States 19 1.8k 0.9× 1.7k 1.3× 260 0.3× 595 2.1× 147 0.7× 48 2.8k
Jason Madore Australia 25 1.6k 0.8× 756 0.6× 1.0k 1.2× 459 1.6× 83 0.4× 32 2.5k
Alejandro D. Ricart United States 24 2.5k 1.3× 1.4k 1.1× 780 0.9× 762 2.6× 100 0.5× 57 4.0k
Amanda L. Christie United States 21 1.0k 0.5× 1.6k 1.2× 275 0.3× 244 0.8× 174 0.9× 34 2.4k

Countries citing papers authored by Omar Eton

Since Specialization
Citations

This map shows the geographic impact of Omar Eton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar Eton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar Eton more than expected).

Fields of papers citing papers by Omar Eton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar Eton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar Eton. The network helps show where Omar Eton may publish in the future.

Co-authorship network of co-authors of Omar Eton

This figure shows the co-authorship network connecting the top 25 collaborators of Omar Eton. A scholar is included among the top collaborators of Omar Eton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar Eton. Omar Eton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smithy, James W., Ronak Shah, Matthew Adamow, et al.. (2024). Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clinical Cancer Research. 30(16). 3407–3415. 4 indexed citations
2.
Smithy, James W., Colleen Maher, Alexander N. Shoushtari, et al.. (2023). Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).. Journal of Clinical Oncology. 41(16_suppl). 9517–9517.
3.
Yu, Peter Paul, Omar Eton, & Louis P. Garrison. (2019). Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. Journal for ImmunoTherapy of Cancer. 7(1). 235–235. 8 indexed citations
4.
Fonkem, Ekokobe, Erik J. Uhlmann, Scott Floyd, et al.. (2012). Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Review of Neurotherapeutics. 12(10). 1207–1215. 56 indexed citations
5.
Dees, Elizabeth Claire, Jeffrey R. Infante, Roger B. Cohen, et al.. (2010). Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(4). 945–954. 64 indexed citations
6.
Lynch, Thomas J., David Fenton, Vera Hirsh, et al.. (2009). A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(8). 1002–1009. 52 indexed citations
7.
Hwang, Cindy S., Víctor G. Prieto, A. Hafeez Diwan, et al.. (2008). Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Research. 18(4). 241–245. 7 indexed citations
8.
Kim, Kevin B., Ángela Sanguino, Nicholas E. Papadopoulos, et al.. (2004). Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 100(7). 1478–1483. 62 indexed citations
9.
Kim, Kevin B., et al.. (2004). Pilot study of high‐dose, concurrent biochemotherapy for advanced melanoma. Cancer. 101(3). 596–603. 11 indexed citations
10.
Bedikian, Agop Y., Nikolaos G. Papadopoulos, Carl Plager, Omar Eton, & Sigrid Ring. (2003). Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Research. 13(3). 303–306. 57 indexed citations
11.
Eton, Omar, Michael G. Rosenblum, Sewa S. Legha, et al.. (2002). Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma. Cancer. 95(1). 127–134. 37 indexed citations
12.
Eton, Omar, Merrick I. Ross, K Itoh, et al.. (1998). Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.. PubMed. 4(3). 619–27. 23 indexed citations
13.
Legha, S S, Sigrid Ring, Omar Eton, et al.. (1998). Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.. Journal of Clinical Oncology. 16(5). 1752–1759. 221 indexed citations
14.
Buzaid, Antônio C., Francis Ali‐Osman, Elizabeth A. Grimm, et al.. (1998). DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Research. 8(2). 145–148. 4 indexed citations
15.
Eton, Omar, S S Legha, Antônio C. Buzaid, et al.. (1998). Prognostic factors for survival of patients treated systemically for disseminated melanoma.. Journal of Clinical Oncology. 16(3). 1103–1111. 167 indexed citations
16.
Tyler, Douglas S., Mitchell J. Frederick, J. L. Smith, et al.. (1995). Interleukin-1 Production in Tumor Cells of Human Melanoma Surgical Specimens. Journal of Interferon & Cytokine Research. 15(4). 331–340. 16 indexed citations
17.
Buzaid, Antônio C., Elizabeth A. Grimm, Francis Ali‐Osman, et al.. (1994). Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Research. 4(5). 327–330. 8 indexed citations
18.
Hayakawa, Kazuhiro, et al.. (1993). Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation. Cancer Immunology Immunotherapy. 37(6). 392–399. 2 indexed citations
19.
Eton, Omar, et al.. (1991). Phase II trial of cisplatin and etoposide in patients with metastatic melanoma. Investigational New Drugs. 9(1). 101–103. 2 indexed citations
20.
Eton, Omar, Dean F. Bajorin, Ephraim S. Casper, & Alan N. Houghton. (1991). Phase II trial of N-methylformamide in patients with metastatic melanoma. Investigational New Drugs. 9(1). 97–100. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel O. Persky Breakdown of academic impact, for papers by Jeff Sosman Breakdown of academic impact, for papers by Chuanliang Cui Breakdown of academic impact, for papers by Thinle Chodon Breakdown of academic impact, for papers by Stan Lipkowitz Breakdown of academic impact, for papers by Kimberly B. Dahlman Breakdown of academic impact, for papers by Nicholas W. Choong Breakdown of academic impact, for papers by Jason Madore Breakdown of academic impact, for papers by Alejandro D. Ricart Breakdown of academic impact, for papers by Amanda L. Christie
Rankless by CCL
2026